Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

LabMinds Successfully Receives Approval for Use in a GMP Certified Laboratory.


LabMinds®, Inc., a pioneer in automation for solution preparation in life sciences, today announced that the Revo has been approved for use in a Good Manufacturing Practice (GMP) certified laboratory in a Top 10 Pharmaceutical company.

LabMinds is an internationally recognized, award-winning robotics company in the pharmaceutical industry. This approval follows a 12-month product development collaboration with a European based pharmaceutical leader. GMP certification was achieved through a series of rigorous process reviews and upgrades. This GMP designation demonstrates that the Revo fulfills the high degree of quality, traceability, documentation and consistency required by the pharmaceutical industry.

"On behalf of the LabMinds team, I would like to thank everyone involved in this GMP product development project. This represents a significant milestone in our commercial growth plans to bring new products and services to market," says Jeff Caputo, President and CEO of LabMinds. "Our customers clearly want to leverage the benefits of our Revo technology in their regulated laboratories. We look forward to launching our GMP product offering globally this year."

About LabMinds Inc. LabMinds is the leader in AI and robotics for solution preparation in pharmaceutical and life science labs. A cornerstone of R&D and QA/QC processes, solution preparation continues to be a highly manual process with many moving parts, exposing labs to considerable risk and inevitable waste. LabMinds' platform addresses these challenges with powerful AI software combined with state-of-the-art robotics to safeguard against tainted inputs, enable near-perfect accuracy, and attain unmatched control. Further, labs in the LabMinds network contribute to, and benefit from, the collection of input and sensor data throughout the solution prep process; it's never been easier to gain detailed insight into how chemicals interact with each other. By implementing more security and order, and leveraging the power of big data, LabMinds moves ever closer to achieving its mission to enable scientists and businesses to build and optimize labs, to bring meaningful therapies to market sooner.


These press releases may also interest you

at 12:30
Cornell Capital LLC ("Cornell Capital") and Trilantic North America, two leading private investment firms, today announced that they have agreed to acquire Fastaff Travel Nursing® ("Fastaff") and U.S. Nursing Corporation® ("U.S. Nursing").  This...

at 12:30
Hand & Stone Massage and Facial Spa, the 475-plus-unit massage and facial spa franchise with a mission to bring affordable massage and facial services to everyday consumers, is launching a new conversion incentive program for franchise owners. The...

at 12:24
Throughout the pandemic, there have been countless examples of Canadians showing kindness and compassion to others as we faced uncertainty and challenges. We know, however, that some Canadians have experienced bullying associated with COVID-19, such...

at 12:16
The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for...

at 12:15
CMI Media Group, the leading media strategy, planning, innovation and buying agency for the nation's top healthcare companies and part of WPP , announced it has been chosen by a top 10 pharmaceutical company to provide programmatic and social...

at 12:01
Innovaccer Inc., a leading healthcare technology company, announced today that it has closed a new round of growth funding at a $1.3 billion post-money valuation, led by Tiger Global Management. Existing investors Steadview Capital, Dragoneer, B...



News published on 19 january 2021 at 19:00 and distributed by: